Nuvalent (NUVL) Cash from Investing Activities (2021 - 2026)
Nuvalent (NUVL) posted Cash from Investing Activities of -$19.4 million for Q1 2026, up 93.09% on a QoQ basis from -$280.9 million in Q4 2025, and down 176.38% year-over-year from $25.4 million in Q1 2025.
Nuvalent (NUVL) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Nuvalent's Cash from Investing Activities history runs 6 years deep, the most recent figure standing at -$19.4 million for Q1 2026.
- Quarterly Cash from Investing Activities fell 176.38% year-over-year to -$19.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$168.9 million (up 50.51% YoY) and the FY2025 annual result came in at -$124.1 million, up 78.37% from the prior year.
- Cash from Investing Activities was -$19.4 million for Q1 2026 at Nuvalent, up from -$280.9 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $77.5 million in Q2 2025 and bottomed at -$280.9 million in Q4 2025.
- A 5-year average of -$51.2 million and a median of $1.6 million in 2023 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities plunged 1074.65% — and 2024, when it soared 916.81%.
- Nuvalent's Cash from Investing Activities stood at -$65.4 million in 2022, then climbed by 13.98% to -$56.3 million in 2023, then plunged by 202.24% to -$170.0 million in 2024, then slumped by 65.22% to -$280.9 million in 2025, then soared by 93.09% to -$19.4 million in 2026.
- Business Quant data shows NUVL's Cash from Investing Activities at -$19.4 million in Q1 2026, -$280.9 million in Q4 2025, and $54.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | -19.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.41 Mn |
| Mar 31, 2026 | -19.41 Mn |
| Dec 31, 2025 | -280.94 Mn |
| Dec 31, 2025 | -280.94 Mn |
| Sep 30, 2025 | 53.97 Mn |
| Sep 30, 2025 | 53.97 Mn |
| Jun 30, 2025 | 77.48 Mn |
| Jun 30, 2025 | 77.48 Mn |
| Mar 31, 2025 | 25.42 Mn |
| Mar 31, 2025 | 25.42 Mn |
| Dec 31, 2024 | -170.05 Mn |
| Dec 31, 2024 | -170.05 Mn |
| Sep 30, 2024 | -212.91 Mn |
| Sep 30, 2024 | -212.91 Mn |
| Jun 30, 2024 | 16.21 Mn |
| Jun 30, 2024 | 16.21 Mn |
| Mar 31, 2024 | -206.77 Mn |
| Mar 31, 2024 | -206.77 Mn |
| Dec 31, 2023 | -56.26 Mn |
| Dec 31, 2023 | -56.26 Mn |